je.st
news
Post-Hoc Analysis of Overall Survival in ...
2014-06-01 22:01:08| Biotech - Topix.net
Celgene Corporation today announced updated Overall Survival results from a post-hoc analysis of its phase III MPACT study of ABRAXANEA in combination with gemcitabine in treatment-naA ve patients with metastatic pancreatic cancer.
Tags: analysis
survival
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||